Regulatory policy as innovation: Constructing rules of engagement for a technological zone of tissue engineering in the European Union

Research Policy

Volumn 38, Issue 4, 2009, Pages 637-646

  Faulkner, Alex ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

European Union; Innovation systems; Regenerative medicine; Regulatory policy; Social constructionism

Indexed keywords

AVIATION; ENGINEERING RESEARCH; LAWS AND LEGISLATION; TECHNOLOGY; TISSUE ENGINEERING;

EUROPEAN UNION; INNOVATION SYSTEMS; REGENERATIVE MEDICINE; REGULATORY POLICY; SOCIAL CONSTRUCTIONISM;

INNOVATION;

EID: 63149158188     PISSN: 00487333     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.respol.2009.01.017     Document Type: Article

References (61)

1. Abraham J., and Lewis G. Regulating Medicines in Europe: Competition, Expertise and Public Health (2000), Routledge, London
2. Abraham J., and Reed T. Progress, innovation and regulatory science in drug development: the politics of international standard-setting. Social Studies of Science 32 3 (2002) 337-369
3. Abraham J., and Davis C. Interpellative sociology of pharmaceuticals: problems and challenges for innovation and regulation in the 21st century. Technology Analysis & Strategic Management 19 3 (2007) 387-402
4. Barry A. Political Machines: Governing a Technological Society (2001), The Athlone Press, London
5. Barry A. Technological zones. European Journal of Social Theory 9 2 (2006) 239-253
6. Blume S.S. Insight and Industry: On the Dynamics of Technological Change in Medicine (1992), MIT Press, Cambridge, MA
7. Bock A.K., Ibarreta D., and Rodriguez-Cerezo E. Human Tissue-engineered Products: Today's Markets and Future Prospects (2003), European Commission, Brussels
8. Brown N., Faulkner A., Kent J., and Michael M. Regulating hybrids: 'Making a Mess' and 'Cleaning Up' in tissue engineering and transpecies transplantation. Social Theory & Health 4 1 (2006) 1-24
9. Bud R. In the engine of industry: regulators of biotechnology, 1970-86. In: Bauer M. (Ed). Resistance to New Technology: Nuclear Power, Information Technology and Biotechnology (1999), Cambridge University Press, Cambridge 293-310
10. Callon M. The sociology of an actor network: the case of the electric vehicle. In: Callon M., Law J., and Rip A. (Eds). Mapping the Dynamics of Science and Technology: Sociology of Science in the Real World (1986), Macmillan, London 19-34
11. Callon M. Europe wrestling with technology. Economy and Society 33 1 (2004) 121-134 (review of Barry, A. Political Machines, 2001)
12. Clarke A.E., Shim J.K., Mamo L., Fosket J.R., and Fishman J.R. Biomedicalization: technoscientific transformations of health, illness, and U.S. biomedicine. American Sociological Review 68 2 (2003) 161-194
13. Conrad P. The shifting engines of medicalization. Journal of Health and Social Behaviour 46 (2005) 3-14
14. Council of the European Union, 2006. Note from General Secretariat to Council on the Proposal for a Regulation on Advanced Therapy Medicinal Products, 9521/06. Council of European Union, Strasboug, 19 May.
15. Delanty G., and Rumford C. Rethinking Europe: Social Theory and the Implications of Europeanization (2005), Routledge, London
16. Earnshaw, D., March 2006. Briefing Note on EC Proposal for a Regulation of the European Parliament and of the Council on Advanced Therapy Medicinal Products 2005, Requested by EU Committee of Environment, Public Health & Food Safety. EC DG Internal Policies of the Union-Policy Dept: Economic & Scientific Policy, Brussels.
17. European Commission. Innovation Tomorrow: Innovation Policy and the Regulatory Framework (2002), DG Enterprise, Brussels
18. EC DG Enterprise. Proposal for a Harmonised Regulatory Framework on Human Tissue Engineered Products (2004), European Commission DG Enterprise, Brussels
19. EC DG Enterprise. Proposal for a Harmonised Regulatory Framework on Human Tissue Engineered Products' Summary of Contributions (2004), European Commission DG Enterprise, Brussels
20. EC DG Enterprise, 2004c. Proposal for a harmonised regulatory framework on human tissue engineered products. In: DG Enterprise Consultation Paper, 6 April 2004. Presented at Stakeholders' Conference, 16 April 2004, Brussels.
21. EC DG Sanco, 2003. Amended proposal for a European and Council Directive on setting standards of quality and safety for the donation, procurement, testing, processing, storage, and distribution of human tissues and cells. COM (2003) 340 final May 2003. http://europa.eu.int/eur-lex/en/com/pdf/2003/com2003_ 0340en01.pdf.
22. EC, 2005. Proposal for a Regulation of the European Parliament and of the Council on Advanced Therapy Medicinal products and Amending Directive 2001/83/EC and Regulation (EC) No. 726/2004. 2005/0227(COD). EC, Brussels, 16 November.
23. EU, 2003. Directive 2003/63/EC of 25 June 2003 amending Directive 2001/83/EC of the European Parliament and of the Council on the Community code relating to medicinal products for human use. Official Journal L 159, 27/06/2003, 0046-0094.
24. EU ENVI-Committee on the Environment, Public Health and Food Safety, 2006. Draft report (PE 371.745v02-00) 22.6.2006 PE 374.483v01-00. Amendments 48-120. http://www.europarl.europa.eu/meetdocs/2004_2009/documents/am/620/620607 /620607en.pdf (accessed 10.07.06).
25. Etzkowitz H., and Leydesdorff L. The dynamics of innovation: from national systems and "Mode 2" to a Triple Helix of university-industry-government relations. Research Policy 29 2 (2000) 109-123
26. EUCOMED, 2006. Position Paper on European Commission Proposal for a Regulation on Advanced Therapy Medicinal Products http://www.eucomed.org/Home/Eucomed%20portal/newsroom/memos/atp/atp.aspx (accessed 04.07.06).
27. Europabio, Eucomed, Emerging Biopharmaceutical Enterprises, 2004. Joint industry comments on proposal for a harmonised regulatory framework on human tissue engineered products: DG Enterprise consultation paper 13 August 2004. http://www.europa-bio.be/positions/hTEPs0804.pdf (accessed 12/04).
28. Faulkner A. Medical Technology into Healthcare and Society: A Sociology of Devices, Innovation and Governance (2008), Palgrave Macmillan, Basingstoke
29. Faulkner A., Geesink I., Kent J., and FitzPatrick D. Human tissue engineered products-drugs or devices?. British Medical Journal 326 (2003) 1159-1160
30. Faulkner, A., Kent, J., Geesink, I., FitzPatrick, D., 2004. Purity and the dangers of innovative therapies: re-ordering regulation and governance in the shaping of tissue-engineered medical technology. In: Paper Presented to EASST/4S Conference 'Public Proofs'. École des Mines, Paris.
31. Faulkner A., Kent J., Geesink I., and Fitzpatrick D. Purity and the dangers of regenerative medicine: regulatory innovation of human tissue engineered technology. Social Science & Medicine 63 (2006) 2277-2288
32. Faulkner A., Geesink I., Kent J., and FitzPatrick D. Tissue-engineered technologies: scientific biomedicine, frames of risk and regulatory regime-building in Europe. Science as Culture 17 2 (2008) 195-222
33. In: Franklin S., and Lock M. (Eds). Remaking Life and Death-Towards an Anthropology of the Biosciences (2003), SAR Press, Santa Fe
34. Funtowicz S., Shepherd I., Wilkinson D., and Ravetz J. Science and governance in the EU-a contribution to the debate. Science and Public Policy 27 5 (2000) 327-336
35. Gibbons M., Limoges C., and Nowotny H. The New Production of Knowledge (1994), Sage, London
36. Glasner P. Banking on immortality? Exploring the stem cell supply chain from embryo to therapeutic application. Current Sociology 53 2 (2005) 355-366
37. Harré R. Material objects in social worlds. Theory, Culture & Society 19 5-6 (2002) 23-33
38. Hedgecoe A., and Martin P. The drugs don't work: expectations and the shaping of pharmacogenetics. Social Studies of Science 33 3 (2003) 327-364
39. Hogle L.F. Claims and disclaimers: whose expertise counts?. Medical Anthropology 21 3 (2002) 275-306
40. Kent J., Faulkner A., Geesink I., and FitzPatrick D. Towards governance of human tissue engineered technologies in Europe: framing the case for a new regulatory regime. Technology Forecasting and Social Change 73 (2006) 41-60
41. Kent, J., Faulkner, A., Geesink, I., FitzPatrick, D., 2006b. Culturing cells, reproducing and regulating the self. Body & Society 12 (2) 1-23. DOI:10.1177/1357034X06064296.
42. Klein H.D., and Kleinman D.L. The Social construction of technology: structural considerations. Science, Technology, & Human Values 27 1 (2002) 28-52
43. Lalis, G., 2006. Genes, cells and tissues: commission proposal on advanced therapies. Presentation to BIO (Biotechnology Industry Organization) International Convention, Chicago, April. http://www.europabio.be/AdvancedTherapies.htm (accessed April 2007).
44. Levidow L., Murphy J., and Carr S. Recasting "Substantial Equivalence"; transatlantic governance of GM food. Science Technology & Human Values 32 1 (2007) 26-64
45. MDA/Medical Device Agency. A Code of Practice for the Production of Human-derived Therapeutic Products (2002), Department of Health, London
46. Majone G. The European Community as a regulatory state. European Community Law 1 (1994) 321-419
47. Malerba F. Innovation in sectoral systems: What we know...and what we would like to know. Presentation to SPRU 40th Anniversary Conference. September 2006, University of Sussex, UK (2006)
48. Malerba, F., 1999. New challenges for sectoral systems of innovation in Europe. In: Presented at DRUID Conference on National Innovation Systems, Industrial Dynamics and Innovation Policy. Rebild, June 9-12, 1999. http://www.druid.dk/uploads/tx_picturedb/ds1999-69.pdf (accessed May 2007).
49. Metcalfe, S., James, A., McMeekin, A., 2004. Distributed Innovation Processes and the Uneven Growth Of Medical Knowledge. IHT Programme Research Findings. http://www.york.ac.uk/res/iht/researchfindings/MetcalfeFindings.pdf (accessed May 2007).
50. Metcalfe, S., James, A., 2001. Emergent innovation systems and the delivery of clinical services: the case of intra-ocular lenses. An ESSY Working Paper. Centre for Research on Innovation and Competition (CRIC) and School of Economic Studies, University of Manchester. http://www.mot.chalmers.se/dept/idy/home/stanmetcalfe.pdf (accessed May 2007).
51. Millstone, E., 2009. Science, risk and governance: radical rhetorics and the realities of reform in food safety governance. Research Policy, doi:10.1016/j.respol.2009.01.012, this issue.
52. Nowotny H., Scott P., and Gibbons M. Re-thinking Science: Knowledge and the Public in an Age of Uncertainty (2001), Routledge, London
53. Powell W., and DiMaggio P. The New Institutionalism in Organizational Analysis (1991), University of Chicago Press, Chicago
54. Rhodes R.A.W. Understanding Governance: Policy Networks, Reflexivity and Accountability (1997), Open University Press, Buckingham
55. SCMPMD (Scientific Committee on Medicinal Products and Medical Devices), 2001a. Opinion on the State of the Art Concerning Tissue Engineering. http://europa.eu.int/comm/food/fs/sc/scmp/out37_en.pdf (accessed 18.03.03).
56. SCMPMD, 2001b. Opinion on the State of the Art Concerning Xenotransplantation. SANCO/SCMPMD/2001/0002. http://europa.eu.int/comm/health/ph_risk/committees/scmp/documents/ out38_en.pdf (accessed 12/04).
57. Sharp L.A. Bodies, boundaries, and territorial disputes: investigating the murky realm of scientific authority. Medical Anthropology 21 (2002) 369-379
58. In: Steffen M. (Ed). Health Governance in Europe: Issues, Challenges and Theories (2005), Routledge, London
59. Vogel, D., 2001. The new politics of risk regulation in Europe. CARR Discussion Paper 3. LSE, London, pp. 1-25.
60. Vos E. Institutional Frameworks of Community Health and Safety Legislation: Committees, Agencies and Private Bodies (1999), Hart, Oxford
61. Waldby C. Stem cells, tissue cultures and the production of biovalue. Health 6 3 (2002) 305-323